Aurobindo Pharma Ltd., the Hyderabad-based pharmaceutical company, experienced a 5% drop in its share price on Friday. The decline followed news that the company’s subsidiary, Eugia Pharma Specialties Ltd., received a warning letter from the United States Food and Drug Administration (USFDA) for its Unit-III facility.
Key Details
- Facility Affected: Eugia Pharma Specialties Ltd., Unit-III
- Location: Pashamylaram
- Issue: USFDA Warning Letter
Background
- Previous Status: In May 2024, the same unit was issued an Official Action Indicated (OAI) status following USFDA observations.
- Warning Letter Purpose: The USFDA issues warning letters to address concerns such as poor manufacturing practices, product claims, or incorrect usage instructions.
Company Response
- Regulatory Status: Aurobindo Pharma stated that there is no immediate impact on existing supplies to the US markets.
- Current Share Price: As of 10:37 AM, shares were trading 2.77% lower at ₹1,477.55.
The warning letter from the USFDA highlights regulatory challenges for Aurobindo Pharma’s Eugia unit, although the company reassures that it does not affect current US market supplies.
TOPICS:
Aurobindo Pharma